Research progress of ALK+diffuse large B-cell lymphoma
10.3969/j.issn.1000-8179.2013.14.016
- VernacularTitle:ALK+弥漫大B细胞淋巴瘤的研究进展*
- Author:
Qianqian FU
;
Tiantian ZHANG
;
Qiongli ZHAI
- Publication Type:Journal Article
- Keywords:
anaplastic lymphoma kinase;
diffuse large B-cell lymphoma;
immunohistochemistry
- From:
Chinese Journal of Clinical Oncology
2013;(14):873-876
- CountryChina
- Language:Chinese
-
Abstract:
Anaplastic lymphoma kinase-positive (ALK+) diffuse large B-cell lymphoma (DLBCL) is a rare subtype of DLBCL. ALK+DLBCL has a characteristic immunoblastic/plasmablastic morphology, a distinct immunophenotypic profile, and recurrent cytoge-netic/molecular genetic abnormalities. The occurrence of this type of lymphoma has been reported in both adult and pediatric popula-tions. Although rare, this new entity should be recognized because most cases follow an aggressive clinical course with a poor progno-sis. The response of ALK+DLBCL to conventional chemotherapy is poor. The recently discovered small molecule ALK inhibitor may provide a potential therapeutic option for patients with this disease.
